Skip to content

stephen horrigan

    • 16h-indexImpact measure calculated using publication and citation counts. Updated daily.
    • 841CitationsNumber of citations received by stephen's publications. Updated daily.

    Groups

    Co-authors (140)

    • Cancer Immunity
    • Jeff Strovel
    • Reinhard Ebner
    • Ken Carter
    • Janak Padia
    • Jeffrey Strovel

    Publications (5)

    • β-catenin inhibitor BC2059 is efficacious as monotherapy or in combination with proteasome inhibitor bortezomib in multiple myeloma

      • Savvidou I
      • Khong T
      • Cuddihy A
      • et al.
      N/AReaders
      2Citations
      Get full text
    • Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors

      • Soldi R
      • Horrigan S
      • Cholody M
      • et al.
      N/AReaders
      4Citations
      Get full text
    • Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells

      • Fiskus W
      • Sharma S
      • Saha S
      • et al.
      N/AReaders
      17Citations
      Get full text
    • Mighty, but how useful? The emerging role of genetically engineered mice in cancer drug discovery and development

      • Ebner R
      • Strovel J
      • Horrigan S
      • et al.
      N/AReaders
      0Citations
      Get full text
    • Genomic-based high throughput screening identifies small molecules that differentially inhibit the antiviral and immunomodulatory effects of IFN-α

      • Chen B
      • Zong Q
      • Cibotti R
      • et al.
      N/AReaders
      3Citations
      Get full text